The impact of enzalutamide on quality of life in men with metastatic hormone‐sensitive prostate cancer based on prior therapy, risk, and symptom subgroups

Enzalutamide plus androgen deprivation therapy (ADT) improved radiographic progression‐free survival versus ADT alone in patients with metastatic hormone‐sensitive prostate cancer (mHSPC) in ARCHES (NCT02677896). While health‐related quality of life (HRQoL) was generally maintained in the intent‐to‐treat population, we further analyzed patient‐reported outcomes (PROs) in defined subgroups.